



UNIVERSITY OF LEEDS

This is a repository copy of *The Long and the Short of it: the Role of Short-course Radiotherapy in the Neoadjuvant Management of Rectal Cancer*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/182197/>

Version: Supplemental Material

---

**Article:**

Slevin, F [orcid.org/0000-0002-7176-904X](https://orcid.org/0000-0002-7176-904X), Hanna, CR, Appelt, A [orcid.org/0000-0003-2792-9218](https://orcid.org/0000-0003-2792-9218) et al. (4 more authors) (2022) The Long and the Short of it: the Role of Short-course Radiotherapy in the Neoadjuvant Management of Rectal Cancer. *Clinical Oncology*, 34 (5). E210-E217. ISSN 0936-6555

<https://doi.org/10.1016/j.clon.2021.12.004>

---

Crown Copyright © 2021 Published by Elsevier Ltd on behalf of The Royal College of Radiologists. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

Table 1: Summary of guideline recommendations regarding pre-operative management of rectal cancer

Guideline	Year	Disease stage/risk factors				
		Very early	Early	Intermediate	Locally advanced	Advanced
		<b>cT1-2 N0</b>	<b>cT1-2 N1-2 or cT3a/b N0 CRM clear</b>  <b>No EMVI</b>	<b>cT3a/b N0 low tumour</b>  <b>cT3a/b N1/2 if mid-high tumour</b>  <b>No EMVI</b>	<b>cT3c/d N0-2 CRM clear; very low tumour; EMVI positive</b>	<b>cT4; lateral nodes involved; CRM threatened/involved</b>
NICE [334]	2020	Surgery alone (local excision or TME)	Pre-operative SCRT or LCRT followed by TME for T3 or N1-2		Pre-operative SCRT or LCRT followed by surgery	Pre-operative SCRT or LCRT followed by surgery
ESMO [3129]	2017	TEM if no adverse features* (TME used as salvage if needed)  TEM + perioperative LCRT if adverse features  Local RT (contact or brachytherapy) is an alternative to local surgery, alone or with LCRT	TME  If cT1 or elderly/frail, may consider TEM	TME  May use SCRT or LCRT pre-operatively if good quality excision cannot be achieved	Pre-operative SCRT or LCRT followed by TME (pre-operative RT used to improve local recurrence rates rather than improve resectability)	Pre-operative LCRT followed by TME  SCRT plus FOLFOX chemotherapy followed by TME
NCCN [320]	2020	TEM	Pre-operative SCRT or LCRT followed by TME plus adjuvant CAPOX/FOLFOX		Pre-operative SCRT or LCRT followed by TME plus adjuvant	TNT (Consider FOLFOXIRI as choice of systemic chemotherapy if T4 N1-

	<p>If adverse features* or T2 disease, do salvage TME (+/- CAPOX/FOLFOX) Or use LCRT/SCRT. If no disease post-RT then observe or CAPOX/FOLOX. If disease still present do TME (+/- CAPOX/FOLFOX)</p> <p>If TME for T1/2 disease reveals T3N0, then: LCRT+ CAPOX/FOLFOX or CAPOX/FOLFOX + LCRT or CAPOX/FOLFOX or observe</p> <p>If TME for T1/2 disease reveals T4N0 or T1-4N1-2, then: CAPOX/FOLFOX + LCRT or LCRT + CAPOX/FOLFOX</p>	<p>Or</p> <p>TNT (see below for definition) followed by TME</p>	<p>CAPOX/FOLFOX</p> <p>Or</p> <p>TNT (see below for definition) followed by TME</p> <p>NB. "Watch and wait" may be an alternative to TME for those with a cCR"</p>	<p>2) followed by TME</p> <p>NB. Watch and wait may be an alternative to TME for those with a cCR IORT may be considered at the time of TME</p>
--	--	---	--	---

ASTRO [342]	2020	Surgery alone  May consider pre-operative LCRT for low tumours to aid sphincter preservation	Pre-operative SCRT or LCRT followed by TME  Consider omission of pre-operative RT for T3a/b N0, EMVI negative, CRM clear, >10 cm from anal verge	Pre-operative SCRT or LCRT followed by TME  If cT3 low (≤5cm from anal verge) tumour, consider CAPOX/FOLFOX before or after LCRT or after SCRT	Pre-operative SCRT or LCRT followed by TME  Consider neoadjuvant CAPOX/FOLFOX chemotherapy in addition to pre-operative LCRT or SCRT for risk factors (T3 ≤5 cm from anal verge; CRM <2 mm; N2; EMVI positive)

CAPOX, capecitabine and oxaliplatin; CRM, circumferential resection margin; EMVI, extramural vascular invasion; FOLFOX, 5-fluorouracil and oxaliplatin; FOLFOXIRI, 5-fluorouracil, oxaliplatin and irinotecan; IORT, intra-operative radiotherapy; LCRT, long course radiotherapy; RT, radiotherapy; SCRT, short course radiotherapy; TME, total mesorectal excision; TEM, Transanal endoscopic microsurgery; TNT, Total neoadjuvant therapy – this involves SCRT or LCRT followed by CAPOX/FOLFOX chemotherapy (approx. 12-16 weeks) or CAPOX/FOLFOX chemotherapy (approx. 12-16 weeks) followed by SCRT or LCRT (NCCN guideline definition); cCR, complete clinical response

\*Adverse features following TEM include: positive margins, sub-mucosal spread, poorly differentiated tumour, lymphovascular invasion. ESMO considers involvement of the middle third of the sub-mucosal layer (or lower) to be an adverse feature (≥sm2) while NCCN considers involvement of the lower third (sm3) to be an adverse feature